Introduction
Phosphatidylinositol 4-kinases (PI4Ks) are best known for providing the substrate for phosphatidylinositol 3-kinase (PI3K) and for producing second messengers (Gehrmann and Heilmeyer, 1998; Heilmeyer et al., 2003; Di and De, 2006) . Two kinds of PI4Ks have been characterized, namely type III phosphatidylinositol (PI) 4-kinases (PI4KIIIa and PI4KIIIb) and type II PI 4-kinases (PI4KIIa and PI4KIIb) (Heilmeyer et al., 2003) . Recent evidence suggests that PI(4)P produced by PI4KIIa has an independent function in its own right beyond that of generally providing a substrate for PI3K. It has been reported that PI4KIIa is important for Wnt signaling in Xenopus embryos and interacts with Dvl (Pan et al., 2008; Qin et al., 2009) . Waugh et al. (2003) reported that PI4KIIa colocalized with valosincontaining protein, a potential prognostic marker for cancer. Xu et al. (2006) found that PI4KIIa is associated with cellugyrin-positive Glut4 vesicles. PI4KIIa has also been shown to be essential in both adaptor complex-1-and adaptor complex-3-dependent membrane trafficking (Wang et al., 2003; Craige et al., 2008) . A recent report showed that PI4KIIa associates with HermanskyPudlak syndrome protein complexes (Salazar et al., 2009) . PI4KIIa is necessary for endosomal trafficking and degradation of activated epidermal growth factor receptor (EGFR) (Minogue et al., 2006) , and it is also a critical player in the exo-endocytic cycle of synaptic vesicles (Guo et al., 2003) . The loss of PI4KIIa in mouse causes late onset degeneration of spinal cord axons (Simons et al., 2009) . On the basis of these reports, it can be seen that research on PI4K functions in its own right is attracting a significant amount of attention.
Of the PI4KIIa functions described above, those involving the Wnt signaling pathway, valosin-containing protein and EGFR all have important roles in tumor progression (Hsuan, 1993; Koesters and von Knebel, 2003; Yamamoto et al., 2004) . In addition, a previous study has shown that most PI kinases have higher activities in cancer cells than in normal cells. Total PI4K activity is also higher in cancer cells (Weber et al., 1996) . Taken together, these results imply that PI4KIIa could be involved in tumor progression. However, the precise function of PI4KIIa in cancer is not known at present.
Multiple genetic mutants contribute to tumor growth either by regulating the proliferation of cancer cells, or by changing the microenvironment of tumor, such as angiogenesis (Hanahan and Folkman, 1996) . Inhibition of tumor angiogenesis has been regarded as an attractive nontoxic means of regulating tumor progression (Folkman, 1971) . One of the key mediators of tumor-induced angiogenesis is hypoxia-inducible factor-1 (HIF-1), a transcription factor that controls the expression of target genes correlated with tumor angiogenesis, such as vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) (Melillo et al., 1995; Ferrara, 2002; Lee et al., 2004) . The activity of HIF-1 is mainly regulated by the state of its O 2 -regulated a-subunit (HIF-1a), and the steady-state level of HIF-1a protein is determined by its level of synthesis and its stability that are regulated by the PI3K and mitogen-activated protein kinase pathways and proteasomal degradation, respectively. HIF-1a has an important role in the regulation of tumor angiogenesis (Lee et al., 2004) .
In this investigation, our aim was to explore the roles of PI4KIIa in tumor growth. Our data show that specific knockdown of PI4KIIa inhibited tumor growth, and this inhibition is correlated with HIF-1a accumulation. Our findings suggest that PI4KIIa may be a promising specific therapeutic target for tumor control.
Results

PI4KIIa is correlated with and has a crucial role in tumor growth
To study the function of PI4KIIa in cancer, we first investigated PI4KIIa and HIF-1a expression at different time points during tumor growth using a xenograft tumor assay. MCA205 fibrosarcoma cells, HeLa cells and MCF-7 cells were inoculated subcutaneously in BALB/c nude mice, and tumor growth was monitored ( Figure 1a ). Parallel to the progression of tumor growth, the expression of PI4KIIa was markedly induced in the three types of tumors (Figure 1b) . At the same time, we also measured the PI4KIIb expression along with tumor growth and found that the PI4KIIb expression increased in MCA205 and MCF-7 cell xenografted tumors, but did not change in HeLa cell xenografted tumors (Supplementary Figure S1) . The expression of HIF-1a in tumor tissues was examined at the same time as a positive control. Consistent with previous reports (Semenza, 2001 (Semenza, , 2002 , HIF-1a increased significantly during tumor growth (Figure 1b) . These results show that both PI4KIIa and HIF-1a are simultaneously upregulated with tumor growth.
To confirm the relationship between tumor growth and PI4KIIa, we examined PI4KIIa expression levels in a 500-core tissue microarray with >18 of the most common types of cancer (nearly 20 cases per type) and normal controls (B5 cases per type) from 495 individual patients. Immunohistochemical staining was performed on a high-density multiple organ cancer and normal tissue array with anti-PI4KIIa. Results for bladder transitional cell carcinoma and nonmalignant normal bladder tissue from the tissue microarray were used as standards for comparison (Supplementary Figure S2A) .
All tissues were scored according to this scheme, and the data are summarized in Table 1 . The results indicate that almost all cancer tissues have high PI4KIIa expression and that PI4KIIa expression is significantly upregulated compared with the corresponding normal tissue in human breast nonspecific infiltrating duct carcinoma, breast infiltrating lobular carcinoma, thyroid papillary carcinoma, thyroid follicular carcinoma, fibrosarcoma, malignant melanoma (dermis) and bladder transitional cell carcinoma. A representative example is shown in Figure 1c . Consistent with a previous report (Minogue et al., 2001) , the tissue microarray showed that PI4KIIa is ubiquitously expressed in human tissues, with levels being higher in the brain, kidney, stomach and lung tissues, and lower in thyroid, fibrous tissue, dermis and breast tissues. Taken together, on the basis of the above observation, we hypothesize that PI4KIIa is correlated with tumor growth and may have an important role in tumor progression.
To identify the site of upregulated PI4KIIa in tumor tissues, we conducted PI4KIIa and hematoxylin-eosin staining on a series of normal and cancerous tissue sample slices collected from patients with breast cancer. As shown in Figure 1d , upregulated PI4KIIa was strictly located in the cytosol of cancer cells, but was not present in other cell types. The staining of a HeLa cell-induced tumor showed the same result (Supplementary Figure S2B ).
To determine whether the upregulated expression of PI4KIIa really has a role in tumor growth, a PI4KIIa downregulated HeLa cell line was generated using an RNA interference technique. PI4KIIa small interfering RNA (siRNA) HeLa cells were injected subcutaneously into one side of the venter of nude mice. As a control, the same amount of control RNA interference-transfected HeLa cells was injected into the opposite side of the same mice. As shown in Figure 2a , the growth of PI4KIIa siRNA HeLa tumors was strongly suppressed compared with that of control siRNA HeLa tumors; on day 18 after tumor cell inoculation when the mean volume of control siRNA HeLa tumors was already more than 1100 mm 3 , the volume of PI4KIIa siRNA HeLa tumors was only B500 mm 3 . To exclude the possibility that this effect was restricted to HeLa cells, PI4KIIa expression was also suppressed in MCF-7 human breast carcinoma cells and HEK-293T cells; downregulation of PI4KIIa expression in both types of cells also led to a marked retardation of tumor growth in nude mice (Figure 2b and c) . We also investigated the expression of PI4KIIa and HIF-1a in both PI4KIIa knockdown tumors and control tumors on the fifteenth day of transplantation. As shown in Figure 2d , both PI4KIIa and HIF-1a were inhibited in PI4KIIa knockdown tumors, indicating that the siRNA for PI4KIIa can last more than 15 days. These results clearly show that blocking PI4KIIa expression in tumor cells suppresses tumor growth in vivo. Thus, we can conclude that PI4KIIa has an important role in tumor progression.
PI4KIIa regulates tumor-induced angiogenesis through endothelial cell migration and tube formation To further investigate the mechanism by which downregulation of PI4KIIa inhibits tumor growth, we first compared the viability of cells overexpressing PI4KIIa (HeLa) and cells downregulated for PI4KIIa expression (HeLa, MCF-7 and HEK-293 cells) with the control using an MTT assay. Results showed that regulation of PI4KIIa expression had no obvious impact on cell growth within 48 h. In addition, we tested the toxic effects of PI4KIIa siRNA on HeLa cells and MCF-7 cells using the LDH assay. Consistent results indicating that the downregulation of PI4KIIa expression did not show significant toxicity on both cells within 48 h were obtained (Supplementary Figure S3) . We then investigated another important factor for tumor growth, namely angiogenesis, by quantifying the hemoglobin content in growing tumors. As shown in Figure 3a , the concentration of hemoglobin in PI4KIIa siRNA HeLa tumors was much less than that in control tumors. In agreement with these results, a high density of CD31-positive cells and well-organized vasculatures were observed in control tumors. However, in PI4KIIa siRNA HeLa tumors, there were mainly small, truncated blood vessels or single endothelial cells dispersed irregularly in the tumor (Figure 3b) . Therefore, the inhibition of tumor growth by the downregulation of PI4KIIa was shown to occur through the suppression of tumor-induced angiogenesis.
As is widely known, angiogenesis depends on endothelial cell survival, migration and formation of new blood vessels (Folkman and Haudenschild, 1980) . For this reason, endothelial tube formation assay is frequently adopted to demonstrate angiogenesis in vitro (Kubota et al., 1988) . As shown in Figure 3c , formation of tubes by human umbilical vein endothelial cells (HUVECs) cultured in supernatants from downregulated PI4KIIa HeLa cells was markedly inhibited and the tube length ratio was reduced to B30% of the control. Consistent with this tube formation result, the 'scratch' wound closure assay showed that HUVECs cultured in supernatants from downregulated PI4KIIa HeLa cells migrated more slowly than did cells in the medium from control HeLa cells (Figure 3d ). Both results indicate that the inhibition of PI4KIIa expression in HeLa cells can markedly influence endothelial cell functions, which further confirmed the above result that PI4KIIa can regulate tumor-induced angiogenesis. We then investigated whether suppression of PI4KIIa in tumor cells could influence VEGF protein expression, as VEGF protein expression has been reported to contribute to angiogenesis in tumors (Ferrara, 2002) . After knockdown of PI4KIIa, both the secreted VEGF protein in the conditional medium ( Figure 3e ) and the VEGF protein retained in cancer cells ( Figure 3f ) were distinctly downregulated. This result confirmed that the expression of PI4KIIa in cancer cells correlates with endothelial cell functions.
Specific regulation of HIF-1a by PI4KIIa in vitro and in vivo As our results showed that both PI4KIIa and HIF-1a are simultaneously upregulated along with tumor growth (Figure 1b) , and HIF-1a is a critical transcription factor associated with tumor-induced angiogenesis (Kung et al., 2000) , the effect of PI4KIIa on HIF-1a expression was investigated in this study. PI4KIIa was downregulated by specific RNA interference in HeLa cells, whereas PI4KIIb expression was not affected. HIF-1a protein expression was markedly inhibited in PI4KIIa-deficient HeLa cells (Figure 4a ) and the effect of PI4KIIa on HIF-1a is also present in MCF-7 cells (Supplementary Figure S4A) .
To confirm the direct regulatory effect of PI4KIIa on HIF-1a, pEGFP-PI4kIIa and green fluorescent protein (GFP) were overexpressed in HEK-293 cells as indicated in Figure 4b . The levels of HIF-1a protein were then detected by western blotting with cells transfected with GFP acting as a negative control, whereas cells treated with 1% O 2 for 24 h acted as positive controls (Jiang et al., 1997) . Results showed that overexpression of PI4KIIa, a novel player in tumor growth J Li et al PI4KIIa leads to a large accumulation of HIF-1a, while HIF-1a expression was also significantly induced by hypoxia (1% O 2 treated for 24 h). To determine whether the effect of PI4KIIa on HIF-1a is dependent on its kinase activity, the kinase-dead mutant GFP-PI4KIIa (K152A) and its mock vector were overexpressed in HEK-293 cells. As shown, the level of HIF-1a was not affected by the kinase-dead mutant GFP-PI4KIIa (K152A), indicating that the PI4KIIa kinase active site is critical for its effect on HIF-1a (Figure 4b) . Furthermore, we examined whether the effect of PI4KIIa siRNA on HIF-1a accumulation can be reversed by direct delivery of PI 4-phosphate (PtdIns(4)P), the production of PtdIns4KIIa. As shown in Supplementary  Figure S4 B, the downregulation of HIF-1a protein level induced by PI4KIIa siRNA was obviously rescued by PtdIns(4)P. With regard to the specificity of the regulatory effect of PI4KIIa on HIF-1a, we also studied the effect of PI4KIIb, another member of the PI4K family, on HIF-1a. As shown in Figure 4b , overexpression of PI4KIIb did not affect HIF-1a level. We then investigated whether overexpression of PI4KIIa could stimulate the transcriptional activity of HIF-1a by measuring the downstream gene expression of VEGF and iNOS, both of which were reported to contribute to angiogenesis (Ferrara, 2002; Garcia-Cardena and Folkman, 1998) . VEGF mRNA and the expression of iNOS protein both were strongly induced by overexpression of PI4KIIa in HeLa cells (Supplementary Figure S5) . All these data indicate that the relationship between PI4KIIa and HIF-1a, and the correlation of PI4KIIa with tumor growth, is subtype specific and is dependent on its enzyme activity. To further determine whether the relationship between PI4KIIa and HIF-1a really exists in vivo, we examined the location of both proteins in the same tumor section by using double fluorescence-labeled staining. PI4KIIa in tumor slices yields a stable red fluorescence, which is clearly visible in most cancer cells, whereas HIF-1a yields a green fluorescence, which was only localized in tumor cells with higher levels of red fluorescence (Figure 4c ). The same result was obtained in tissues from human breast cancer patients described above (data not shown). These results indicate that HIF1a localized in cancer cells with high-expressed PI4KIIa, and that HIF-1a is correlated with upregulated PI4KIIa in vivo.
PI4KIIa triggers HIF-1a accumulation through a translation-dependent pathway involving the HER-2/PI3K, ERK1/2 cascades Many reports have concluded that mechanisms responsible for increasing expression of HIF-1a can be divided into two categories, namely increasing protein synthesis and decreasing ubiquitination of HIF-1a (Semenza, 2002; Lee et al., 2004) . To obtain a better understanding of the processes involved in the increase of HIF-1a protein in response to overexpression of PI4KIIa, we analyzed HIF-1a protein synthesis by performing a time PI4KIIa, a novel player in tumor growth J Li et al course of HIF-1a disappearance in the presence of the protein translation inhibitor, cycloheximide. HEK-293 cells were transiently transfected with GFP-PI4KIIa or treated with hypoxia (1% O 2 ) for 24 h, then incubated with cycloheximide for 15, 30 or 60 min. In PI4KIIa-overexpressing HEK-293 cells, cycloheximide led to a decrease in the level of HIF-1a protein after 15 min and HIF-1a protein was no longer detectable after 60 min, but no changes were observed in levels of either overexpressed GFP-PI4KIIa or endogenous PI4KIIa (Figure 5a ). In cells exposed to hypoxia, the level of HIF-1a remained constant over a 60-min period (Figure 5b ), which was consistent with previous studies showing that hypoxia caused HIF-1a accumulation mainly by blocking its degradation. To confirm whether PI4KIIa can change HIF-1a mRNA expression, HEK-293 cells were transfected with GFP-PI4KIIa and reverse transcriptase-PCR was performed using a HIF-1a cDNA probe (Figure 5c ). Just as was the case with hypoxia treatment, overexpression of PI4KIIa did not change the level of HIF-1a mRNA. Taken together, these results suggest that PI4KIIa triggers HIF-1a accumulation through a translation-dependent pathway. According to previous studies, the increase in the synthesis of HIF-1a protein is mainly mediated through the PI3K and mitogen-activated protein kinase pathways (Hellwig-Burgel et al., 1999; Zhong et al., 2000; Treins et al., 2002) . Therefore, we examined the effect of inhibitors against PI3K (LY294002) or extracellular signal-regulated protein kinase (ERK)1/2 (U0126) on the accumulation of HIF-1a triggered by overexpression of PI4KIIa. As shown in Figure 5d , both LY294002 and U0126 can reduce the expression of HIF-1a induced by overexpression of PI4KIIa, but neither of them inhibited the induction totally. Genes downstream of HIF-1a, iNOS and VEGF, were also analyzed and results were consistent with the above finding: both PI3K and ERK1/2 inhibitors can reduce VEGF mRNA and iNOS protein levels triggered by overexpression of PI4KIIa. Moreover, suppression PI4KIIa expression in HeLa cells obviously inhibited the phosphorylation of both ERK1/2 and AKT (Supplementary Figure S6) .
As is well known, receptor tyrosine kinase activation is the main factor causing increased HIF-1a synthesis, and functions through the PI3K and mitogen-activated protein kinase pathways (Lee et al., 2004) ; therefore, we hypothesize that PI4KIIa may exert effects on kinases of the epidermal growth factor (EGF)-receptor (also known as ERBB) family, which is a representative subgroup of the receptor tyrosine kinase family. As we have found that suppression of PI4KIIa has the greatest inhibiting effect on breast cancer MCF-7 cell-induced tumor growth, and the expression of PI4KIIa is markedly increased in breast cancer compared with normal breast tissue, the activity of ERBB2 (also known PI4KIIa, a novel player in tumor growth J Li et al as HER-2/neu, which is especially important for breast cancer (Roskoski, 2004 ) was chosen for examination. As shown in Figure 5e , downregulation of PI4KIIa markedly reduced the autophosphorylation of HER-2 at Tyr1248 under 100 ng/ml EGF stimulation for 20 min, and did not influence its protein level. All the above results indicate that PI4KIIa regulates HIF-1a synthesis through the HER-2/PI3K, ERK pathway.
Discussion
During tumor progression, the expression of many proteins such as HIF-1a, VEGF and HER-2 is upregulated (Ferrara, 2002; Lee et al., 2004; Roskoski, 2004) , most of which have very important functions in this process. Oncogenes have very important roles in tumor progression. In this study, we found that PI4KIIa has a close relationship with tumor progression: PI4KIIa is significantly upregulated along with tumor growth, and the increased protein levels are strictly localized in cancer cells (Figure 1) . What is of greater interest is that specific suppression of PI4KIIa expression can strongly inhibit xenograft tumor growth in vivo (Figure 2 ). On the basis of our research, we propose a model for the mechanism of PI4KIIa in tumor growth: environmental stress causes an increase in PI4KIIa protein levels in cancer cells, and the elevated PI4KIIa levels lead to increased HER-2 activities, which can increase HIF-1a protein accumulation in the PI3K-and ERK1/2-dependent pathways. The increased HIF-1a activates the expression of its proangiogenesis target PI4KIIa, a novel player in tumor growth J Li et al genes, such as VEGF and iNOS, to promote endothelial cell migration and tubulogenesis, contributing to tumor angiogenesis. Knockdown of PI4KIIa in tumor cells significantly inhibits this pathway and suppresses tumor growth ( Figure 6 ). To our knowledge, this is the first report to suggest that PI4KIIa is crucial for the regulation of tumor-induced angiogenesis through HIF-1a.
With respect to the role of PI4K in cancer, a previous study simply reported that most PI kinases have higher activities in cancer cells (Weber et al., 1996) . In this study, we determined that it is the protein level of one specific subtype, PI4KIIa, that increases in several types of human cancer and that the upregulation of PI4KIIa directly contributes to tumor progression. Results from our tumor microarray study strongly indicate that 95% of malignant melanomas (dermis), 88.9% of human breast nonspecific infiltrating duct carcinomas, 76.9% of breast infiltrating lobular carcinomas, nearly 100% of thyroid papillary carcinomas, 100% of thyroid follicular carcinomas, 100% of fibrosarcomas and 100% of bladder transitional cell carcinomas have elevated PI4KIIa expression levels compared with normal tissues. However, we were not able to conclude whether PI4KIIa expression also changes in the other 13 types of cancer tested (Table 1) , as all the samples were displayed on the same chip-it is hard to control staining conditions so that they are suitable for each sample. These results show that these 13 types of cancer all have high levels of PI4KIIa expression in both cancer and normal samples. In this study, three different tumor cell lines (namely HeLa, MCF-7 and HEK-293) were used to test the effects of PI4KIIa on tumor growth. Downregulation of PI4KIIa resulted in a clear inhibition of tumor growth in all these cell lines, particularly in MCF-7 cell-induced tumors, in which tumor growth was almost completely inhibited (Figure 2b ). Taken together with results obtained from the human tumor microarray, we can conclude that PI4KIIa is an effective target for tumor control in more than one tumor type. However, its efficacy may vary with different tumor types. One point to be addressed is that both overexpressing PI4KIIa and its kinase-dead mutant PI4-KIIak152A in HeLa cells had no significant effect on the growth of tumor transplants (Supplementary Figure  S7) . The reason for this might be that the upregulation of endogenous PI4KIIa on tumor growth is so strong that the effects of overexpressed exogenous PI4KIIa are largely submerged. A very recent study showed that inositol polyphosphate 4-phosphatase type II (INPP4B) is a tumor suppressor (Gewinner et al., 2009) . Several aspects of this study were consistent with our work, for example, the overexpression of INPP4B in SUM 149 cells reduced tumor growth in a xenograft mouse model by suppressing the PI3K/AKT signaling pathway, and INPP4B is frequently deleted in various solid tumors, including basal-like breast cancer. As known, the relationship between PI4K and INPP4B is similar to PI3K and PTEN; thus, both studies suggested that the D-4 position phosphorylated productions of PI are essential for tumor growth. In this regard, the regulation of D-4 position phosphorylation of PIs is a multimechanism in tumor progression.
With respect to the regulation of the HER-2 signaling pathway by PI4KIIa, there have been some reports about the relationship between PI4KIIa and different ERBB families: Scott et al. (1991) showed that PI4K activity increased after stimulation of the ERBB-2 (HER-2) receptor tyrosine kinase in overexpressing breast cancer cells (Scott et al., 1991) . Kauffmann-Zeh et al. (1994) reported that EGF regulates PI4KIIa activity and is associated with ERBB-1 (EGFR), and Minogue et al. (2006) showed that PI4KIIa can influence the endosomal trafficking and degradation of EGFR. However, none of these reports show a direct effect of PI4KIIa on kinase activity. In this study, we report that regulation of PI4KIIa expression can markedly influence the autophosphorylation of HER-2 at Tyr1248, which may impact members of the signaling pathway downstream of HER-2, such as PI3K and ERK, therefore contributing to the accumulation of HIF-1a, a very important molecule for tumor-induced angiogenesis ( Figure 5 ). It was also interesting to discover that the effect of PI4KIIa on HIF-1a is subtype specific and kinase activity dependent (Figure 4) , similar to the effects of PI4KIIa on the Wnt signaling pathway and on adaptor complex-1 and adaptor complex-3 functions (Wang et al., 2003; Craige et al., 2008; Pan et al., 2008) . Although we are still not clear about the detailed mechanism, we hypothesize that the effect of PI4KIIa on the HER-2 signal transduction cascade may Figure 6 A model for the mechanism of PI4KIIa action in tumor growth. Environmental stress causes an increase in PI4KIIa protein levels, and the elevated PI4KIIa leads to increased HER-2 activities, which can increase HIF-1a protein accumulation in the PI3K-and ERK1/2-dependent pathways. The accumulated HIF1a can heterodimerize with HIF-1b to activate the transcription of downstream proangiogenic genes, such as VEGF and iNOS, which can promote endothelial cell migration and tubulogenesis. As a result, tumor growth is promoted by the enhanced angiogenesis. Knockdown of PI4KIIa significantly inhibits this pathway and represses tumor growth.
be through a similar mechanism to that for its effect on the Wnt signal pathway: suppression of PI4KIIa may influence the formation of PtdIns(4)P and PtdIns(4,5)P 2 in the plasma membrane, which are essential for HER-2 heterodimerization with other members of the ERBB family, such as EGFR, HER-3 and HER-4. Further investigation of this mechanism will be of value in future studies.
With respect to the function of PI4KIIa in angiogenesis, we found that supernatants from downregulated PI4KIIa HeLa cells significantly inhibited endothelial migration and tube formation. What is more, the proangiogenic gene VEGF produced by HeLa cells both in supernatants and cell lysates was dramatically reduced after PI4KIIa knockdown (Figure 3 ). Further study indicated that PI4KIIa can directly influence the accumulation of HIF-1a (Figure 4a and b) , an important regulator of VEGF in tumor progression (Huang and Bunn, 2003) . Moreover, we found that HIF-1a was mainly located in cancer cells overexpressing PI4KIIa (Figure 4c ), in accordance with in vitro observations, confirming the correlation between PI4-KIIa and HIF-1a in vivo. All these results provide a good explanation for the effect of PI4KIIa on angiogenesis. Therefore, PI4KIIa is a novel player in tumor control through the regulation of angiogenesis.
To our knowledge, this is the first time that the pivotal role of PI4KIIa in the regulation of tumor growth through angiogenesis and HIF-1a has been demonstrated in its own right. Our findings indicate that PI4KIIa is a new player in the orchestration of tumor control. In addition, PI4KIIa is just one subtype of the PI4K family; thus, specific downregulation of PI4KIIa will not induce complicated side effects because other PI4K family members remain functional. Therefore, PI4KIIa may be a promising target for tumor therapy.
Materials and methods
Human cancer specimens A multiple organ cancer tissue and normal tissue microarray was purchased from Chaoying Biotechnology Company (Shanxi, China). Patient breast cancer tissues and the corresponding cancer adjacent normal tissues were obtained from Xuanwu Hospital (Capital Medical University, Beijing, China). All patients consented to the use of their tissues for research projects.
Analysis of hemoglobin content in tumors
Hemoglobin content in isolated tumors was estimated by Drabkin's cyanmethemoglobin method (Drabkin, 1949) . Hemoglobin values were calculated using a hemoglobin standard curve prepared using serial dilutions of mouse blood.
Endothelial cell scratch wound healing assay and tube formation assay HeLa cells were transfected with control siRNA or PI4KIIa siRNA as described above. After a 72-h incubation period, the culture medium was changed with fresh medium containing 10% fetal bovine serum, and the supernatant from both types of transfected cells was collected after a further 24-h incubation period. Confluent HUVEC monolayers were 'scratch' wounded and then rinsed with phosphatebuffered saline. The above supernatants were then added separately to the wells. After incubation for 24 h, cells were stained with Hoechst 33342, and then observed on a laserscanning confocal microscope (Olympus FV500, Olympus, Tokyo, Japan). Three measurements taken randomly were obtained for each treatment and the experiment was repeated three times. The endothelial tube formation assay was performed as described previously with the following modifications (Grant et al., 1992) . HUVECs were cultured in either of the HeLa cell media described above. The HUVEC tube length was analyzed using Scion Image analysis software (Scion, Frederick, MD, USA). Changes in tube length were normalized as the tube length ratio.
Animal studies
Six-to-eight-week old male BALB/c nude mice (purchased from Weitonglihua, Beijing, China) were allowed to acclimatize for 1 week under specific pathogen-free conditions in the animal facility of the Institute of Biophysics, Chinese Academy of Sciences. All procedures involving animals and their care were approved by the corresponding authorities. In all, 200 ml suspensions of treated cells (HeLa cells, MCA205 tumor cells or MCF-7 cells, phosphate-buffered saline; 2.5 Â 10 7 cells per ml) and their controls were subcutaneously injected into BALB/c nude mice at each venter region and tumor growth was monitored every 2 days. The tumor volumes were calculated (Tan et al., 2004) and tumor tissues were isolated on the days indicated for the measurement of PI4KIIa and HIF-1a protein levels by western blotting and immunohistochemical analysis.
Statistical analysis
Statistical analyses were performed using the two-tailed paired Student t-test. We considered data statistically significant when the P-value was o0.05. All data are expressed as means ± s.d.
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